Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day".

119th Congress Introduced by Jake Auchincloss and 26 co-sponsors

The bill designates July 15, 2026 as Glioblastoma Awareness Day and calls for increased awareness, support for research, and collaboration to improve treatments and outcomes.

Submitted in House

Bill Summary: H.Res. 1270 (119th Congress)

Purpose

Expresses support for designating July 15, 2026, as “Glioblastoma Awareness Day.”

Aims to raise public awareness about glioblastoma, its prognosis, and the ongoing need for research and improved treatments.

Key Provisions and Provisions Details

Statement of support:

The House of Representatives expresses support for designating July 15, 2026, as Glioblastoma Awareness Day.

Public awareness and recognition:

Encourages increased public awareness of glioblastoma.
Honors individuals who have died from glioblastoma or are currently living with the disease.

Support for research and treatment:

Supports efforts to develop better treatments to improve long-term prognosis and quality of life for those diagnosed.
Recognizes the importance of molecular biomarker testing in diagnosis and treatment.
Encourages collaboration among governmental, private, and nonprofit organizations to advance brain tumor research.
Encourages continued investments in glioblastoma research and treatments, including through the Glioblastoma Therapeutics Network (GTN) and other brain tumor resources.

Human impact and support networks:

Expresses support for individuals battling brain tumors and for their families, friends, and caregivers.

Legislative stance:

Emphasizes a collaborative approach and ongoing investment in glioblastoma research as a policy priority.

Who/What Is Affected

Affects: House adoption and public commemoration practices, as the resolution functions as an expression of Congress.

Stakeholders highlighted:

Glioblastoma patients and survivors
Families, caregivers, and friends of those affected
Researchers and institutions involved in glioblastoma and brain tumor research
Agencies and organizations participating in the Glioblastoma Therapeutics Network and related efforts

Procedural and Timeline Aspects

Introduction date: May 7, 2026.

Referred to the House Committee on Energy and Commerce (no further action listed in the provided text).

No substantive budgetary or regulatory changes are proposed; the resolution is a commemorative expression and call to action for awareness and research collaboration.

Background Context (as Presented in the Preamble)

Glioblastoma is described as the most common and most aggressive malignant brain tumor with a low 5-year survival rate (7.1%) and median survival around 9 months.

Highlights the lack of screening/early detection methods and the limited number of FDA-approved treatments specific to glioblastoma (only 5 drugs and 1 medical device since the 1920s).

Notes the National Cancer Institute’s Glioblastoma Therapeutics Network (GTN), established in 2020, to support multi-institutional research and accelerate development of therapies.

Underlines the high out-of-pocket costs for brain cancer patients and the urgent need for awareness and funding to advance research and treatment.

Practical Impact

Serves as a formal congressional acknowledgment intended to:

Promote awareness and education about glioblastoma.
Honor those affected and support the communities around them.
Encourage continued and enhanced investment in research infrastructure and collaborative efforts to develop new treatments and improve patient outcomes.